Xianghong Jasmine Zhou
Overview
Explore the profile of Xianghong Jasmine Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Zhou Y, Yu J, Kim Y, Li M, Lee D, et al.
Nat Biotechnol
. 2024 May;
PMID: 38744947
Cancer immunotherapy with autologous chimeric antigen receptor (CAR) T cells faces challenges in manufacturing and patient selection that could be avoided by using 'off-the-shelf' products, such as allogeneic CAR natural...
2.
Stackpole M, Zeng W, Li S, Liu C, Zhou Y, He S, et al.
Nat Commun
. 2024 May;
15(1):3693.
PMID: 38693151
No abstract available.
3.
Li S, Hu R, Small C, Kang T, Liu C, Zhou X, et al.
Nat Protoc
. 2024 Jan;
19(4):1289.
PMID: 38172643
No abstract available.
4.
Yildirim A, Hua N, Boninsegna L, Zhan Y, Polles G, Gong K, et al.
Nat Struct Mol Biol
. 2023 Aug;
30(8):1193-1206.
PMID: 37580627
The nuclear folding of chromosomes relative to nuclear bodies is an integral part of gene function. Here, we demonstrate that population-based modeling-from ensemble Hi-C data-provides a detailed description of the...
5.
Li S, Zeng W, Ni X, Liu Q, Li W, Stackpole M, et al.
Proc Natl Acad Sci U S A
. 2023 Jul;
120(28):e2305236120.
PMID: 37399400
Plasma cell-free DNA (cfDNA) is a noninvasive biomarker for cell death of all organs. Deciphering the tissue origin of cfDNA can reveal abnormal cell death because of diseases, which has...
6.
Li S, Hu R, Small C, Kang T, Liu C, Zhou X, et al.
Nat Protoc
. 2023 Feb;
18(5):1563-1583.
PMID: 36849599
Cell-free DNA (cfDNA) in blood, viewed as a surrogate for tumor biopsy, has many clinical applications, including diagnosing cancer, guiding cancer treatment and monitoring treatment response. All these applications depend...
7.
Stackpole M, Zeng W, Li S, Liu C, Zhou Y, He S, et al.
Nat Commun
. 2022 Sep;
13(1):5566.
PMID: 36175411
Early cancer detection by cell-free DNA faces multiple challenges: low fraction of tumor cell-free DNA, molecular heterogeneity of cancer, and sample sizes that are not sufficient to reflect diverse patient...
8.
Sun N, Zhang C, Lee Y, Tran B, Wang J, Kim H, et al.
Hepatology
. 2022 Jul;
77(3):774-788.
PMID: 35908246
Background And Aims: The sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this...
9.
Boninsegna L, Yildirim A, Polles G, Zhan Y, Quinodoz S, Finn E, et al.
Nat Methods
. 2022 Jul;
19(8):938-949.
PMID: 35817938
A multitude of sequencing-based and microscopy technologies provide the means to unravel the relationship between the three-dimensional organization of genomes and key regulatory processes of genome function. Here, we develop...
10.
Hu R, Zhou X, Li W
J Comput Biol
. 2022 Jun;
29(8):769-781.
PMID: 35671506
Developing cancer prognostic models using multiomics data is a major goal of precision oncology. DNA methylation provides promising prognostic biomarkers, which have been used to predict survival and treatment response...